Abstract

Ovarian cancer is one of the leading causes of female death and the development of novel therapeutic approaches is urgently required. Nuclear factor-κB (NF-κB) is constitutively activated in several types of cancer including ovarian cancer and is known to support the survival of cancer cells. However, molecular mechanisms of persistent activation of NF-κB in ovarian cancer remain largely unknown. We report here that, in addition to the previously reported canonical activation, NF-κB is activated through the noncanonical pathway in ovarian cancer cells. RNA interference-mediated silencing of NF-κB inducing kinase (NIK), a central regulator of the noncanonical pathway, reduced the NF-κB2/p52 DNA binding activity and NF-κB-dependent reporter gene expression as well as NF-κB target gene expression. Notably, anchorage-dependent and -independent cell growth was impaired in NIK-depleted cells. Depletion of NIK also suppressed tumor formation in the nude mouse xenograft assay. These results indicate that NIK plays a key role in constitutive NF-κB activation and the progression of ovarian cancer cells and suggest that NIK represents an attractive therapeutic target for ovarian cancer.

Highlights

  • Epithelial ovarian cancer is one of the most lethal gynecological malignancies and its survival rate is much lower than other cancers that affect women

  • Activation of the canonical pathway is mainly triggered by cytokine stimuli such as tumor necrosis factor-a (TNFa) and interleukin-1b, followed by activation of the IkB kinase (IKK) complex, which consists of two protein kinases IKKa and IKKb and a regulatory protein Nuclear factor-kB (NF-kB) essential modulator (NEMO named IKKc)

  • The noncanonical NF-kB pathway is activated through particular TNF receptor family members such as B cell-activating factor (BAFF) receptor, CD40 and lymphotoxin beta receptor that bind to the TNF receptor-associated factor (TRAF) 2 or TRAF3

Read more

Summary

Introduction

Epithelial ovarian cancer is one of the most lethal gynecological malignancies and its survival rate is much lower than other cancers that affect women. P52 production requires IkB kinase (IKK)-induced phosphorylation and proteasome-mediated processing of p100. Activated IKK-induced phosphorylation of IkBa leads to its polyubiquitination and proteasomal degradation, followed by translocation of the p50-RelA heterodimer to the nucleus and induction of target gene expression. In response to stimulation with cytokines such as BAFF or CD40 ligand, TRAF3 is recruited to the receptor and undergoes ubiquitination-mediated proteasomal degradation. This results in stabilization and accumulation of newly synthesized NIK, while these stimuli do not increase the NIK mRNA level [3,4]. In contrast to the activation of the canonical pathway, noncanonical NF-kB activation does not require association of NEMO with the IKK complex and is relatively persistent [9]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call